Management of metastatic bladder cancer
Top Cited Papers
- 31 May 2019
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 76, 10-21
- https://doi.org/10.1016/j.ctrv.2019.04.002
Abstract
No abstract availableThis publication has 99 references indexed in Scilit:
- An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancersNature Genetics, 2013
- Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic TargetingPLOS ONE, 2013
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialThe Lancet Oncology, 2012
- Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal functionEuropean Journal of Cancer, 2012
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987Journal of Clinical Oncology, 2012
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986Journal of Clinical Oncology, 2012
- Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium TrialUrology, 2010
- Phase 2 trial of sorafenib in patients with advanced urothelial cancerCancer, 2009
- A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102Annals of Oncology, 2009
- Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapyAnnals of Oncology, 2007